Zanamivir
From Proteopedia
(Difference between revisions)
| Line 2: | Line 2: | ||
{| class="wikitable" border="1" width="52%" style="text-align:center" | {| class="wikitable" border="1" width="52%" style="text-align:center" | ||
|- | |- | ||
| - | ! colspan="12" align="center"| Neuraminidase Inhibitor [[ | + | ! colspan="12" align="center"| Neuraminidase Inhibitor [[Pharmacokinetics]]<ref>A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009</ref><ref>DOI: 10.1007/s00228-003-0639-6</ref> |
|- | |- | ||
! Parameter | ! Parameter | ||
| Line 8: | Line 8: | ||
! [[Oseltamivir]] | ! [[Oseltamivir]] | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr) |
! 1.25 | ! 1.25 | ||
! 1.5 | ! 1.5 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml) |
! 31.6 | ! 31.6 | ||
! 57 | ! 57 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%) |
! 2 | ! 2 | ||
! 75 | ! 75 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%) |
! 10 | ! 10 | ||
! 42 | ! 42 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr) |
! 3 | ! 3 | ||
! 3.2 | ! 3.2 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) |
! 185 | ! 185 | ||
! 204 | ! 204 | ||
|- | |- | ||
| - | ! [[ | + | ! [[Pharmacokinetics#Clearance_.28Cl.29|Clearance]] (L/h) |
! 54.1 | ! 54.1 | ||
! 18.8 | ! 18.8 | ||
Revision as of 12:54, 9 December 2010
Pharmacokinetics
| Neuraminidase Inhibitor Pharmacokinetics[1][2] | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Parameter | Ritonavir | Oseltamivir | |||||||||
| Tmax (hr) | 1.25 | 1.5 | |||||||||
| Cmax (ng/ml) | 31.6 | 57 | |||||||||
| Bioavailability (%) | 2 | 75 | |||||||||
| Protein Binding (%) | 10 | 42 | |||||||||
| T1/2 (hr) | 3 | 3.2 | |||||||||
| AUC (ng/ml/hr) | 185 | 204 | |||||||||
| Clearance (L/h) | 54.1 | 18.8 | |||||||||
| Dosage (mg) | 10 | 300 | |||||||||
| Metabolism | None | Hepatic | |||||||||
- ↑ A Randomized, Placebo Controlled, 3-Way Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir (RELENZA™) 10mg Administered Twice Daily for 5 Days by Rotacap/Rotahaler Compared to ROTADISK™/DISKHALER™ in Healthy Subjects, Study No: NAI113625, 2009
- ↑ Oo C, Hill G, Dorr A, Liu B, Boellner S, Ward P. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1-5 years. Eur J Clin Pharmacol. 2003 Sep;59(5-6):411-5. Epub 2003 Aug 9. PMID:12910331 doi:http://dx.doi.org/10.1007/s00228-003-0639-6
